<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634825</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGA271-06</org_study_id>
    <nct_id>NCT04634825</nct_id>
  </id_info>
  <brief_title>Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer</brief_title>
  <official_title>A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab&#xD;
      administered as first-line treatment to patients with recurrent or metastatic squamous cell&#xD;
      carcinoma of the head and neck.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Enrollment into each cohort will occur independently in a non-randomized fashion, based on PD-L1 expression results. Patients may not crossover between cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of enoblituzumab plus retifanlimab</measure>
    <time_frame>28 months</time_frame>
    <description>Investigator-assessed objective response rate (complete response [CR] or partial response [PR])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of enoblituzumab plus tebotelimab</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of enoblituzumab plus tebotelimab</measure>
    <time_frame>28 months</time_frame>
    <description>Investigator-assessed objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>28 months</time_frame>
    <description>Time from the first dose date to the date of first documented progression or death from any cause, whichever occurs first, evaluated by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-control rate</measure>
    <time_frame>28 months</time_frame>
    <description>Percentage of response-evaluable patients with CR, PR, or stable disease (SD) for at least 3 months, evaluated by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>28 months</time_frame>
    <description>Time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first, evaluated by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>28 months</time_frame>
    <description>Time from the first dose date to the date of death from any cause, evaluated by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of enoblituzumab plus retifanlimab</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of enoblituzumab plus retifanlimab</measure>
    <time_frame>up to 42 weeks</time_frame>
    <description>Serum concentration of enoblituzumab and retifanlimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of enoblituzumab plus tebotelimab</measure>
    <time_frame>up to 42 weeks</time_frame>
    <description>Serum concentration of enoblituzumab and tebotelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of enoblituzumab or retifanlimab</measure>
    <time_frame>28 months</time_frame>
    <description>Proportion of patients who develop anti-drug antibodies to enoblituzumab or retifanlimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of enoblituzumab or tebotelimab</measure>
    <time_frame>28 months</time_frame>
    <description>Proportion of patients who develop anti-drug antibodies to enoblituzumab or tebotelimab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Retifanlimab Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tebotelimab Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Enoblituzumab</intervention_name>
    <description>Anti-B7-H3 antibody</description>
    <arm_group_label>Retifanlimab Cohort</arm_group_label>
    <arm_group_label>Tebotelimab Cohort</arm_group_label>
    <other_name>MGA271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Retifanlimab</intervention_name>
    <description>Anti-PD-1 antibody</description>
    <arm_group_label>Retifanlimab Cohort</arm_group_label>
    <other_name>INCMGA00012, MGA012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tebotelimab</intervention_name>
    <description>PD-1 X LAG-3 bispecific DART molecule</description>
    <arm_group_label>Tebotelimab Cohort</arm_group_label>
    <other_name>MGD013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, recurrent or metastatic squamous cell carcinoma of the head and&#xD;
             neck (SCCHN) not curable by local therapy&#xD;
&#xD;
          -  No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the&#xD;
             exception of systemic therapy completed &gt; 6 months prior if given as part of&#xD;
             multimodal treatment for locally advanced disease)&#xD;
&#xD;
          -  Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Patients&#xD;
             may not have a primary tumor site of upper esophagus, salivary gland, or nasopharynx&#xD;
             (any histology)&#xD;
&#xD;
          -  Availability of formalin-fixed, paraffin embedded tumor specimen or contemporary&#xD;
             biopsy for immunohistochemical evaluation of pharmacodynamic markers of interest&#xD;
&#xD;
          -  Willing to consent for baseline and on-treatment biopsy.&#xD;
&#xD;
          -  Performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy of 6 months or more&#xD;
&#xD;
          -  Adequate end organ function&#xD;
&#xD;
          -  At least one radiographically measurable lesion&#xD;
&#xD;
          -  PD-L1 expression level that is either&#xD;
&#xD;
               1. Positive (combined positive score [CPS] â‰¥ 1) for the retifanlimab cohort, or&#xD;
&#xD;
               2. Negative (CPS &lt; 1) for the tebotelimab cohort&#xD;
&#xD;
          -  Results available from human papilloma virus p16 status for oropharyngeal cancer&#xD;
&#xD;
          -  Acceptable laboratory results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease suitable for local therapy administered with curative intent&#xD;
&#xD;
          -  Progressive disease within 6 months of completion of curatively intended systemic&#xD;
             treatment for locoregionally advanced SCCHN&#xD;
&#xD;
          -  Radiation or other non-systemic therapy within 2 weeks prior to the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Prior therapy with an anti-B7-H3, anti-PD-1, anti-PD-L1, or anti-LAG-3 agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chet Bohac, MD PharmD MSc</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Brann</last_name>
    <phone>(240) 552-8023</phone>
    <email>branns@macrogenics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Petrillo-Myers</last_name>
    <phone>301-675-7022</phone>
    <email>petrillomyersm@macrogenics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland, Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann Alimurong</last_name>
      <phone>410-328-2703</phone>
      <email>Joann.Alimurong@UMM.EDU</email>
    </contact>
    <investigator>
      <last_name>Ranee Mehra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francis P Worden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khin Win, MBA MB BS</last_name>
      <phone>702-968-3834</phone>
      <email>khin.win@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Vicuna, RN</last_name>
      <phone>702-968-3880</phone>
    </contact_backup>
    <investigator>
      <last_name>Grzegorz Obara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Lineberger Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center- Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Ruth</last_name>
      <phone>412-623-8963</phone>
      <email>ruthj2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dan Zandberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health, Medical Oncology Department</name>
      <address>
        <city>Ruse</city>
        <state>New South Wales</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre Southport</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Andrew Love Cancer Centre, Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center Ruse Ltd.</name>
      <address>
        <city>Dobrich</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT Serdica</name>
      <address>
        <city>Panagyurishte</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MBAL Uni Hospital</name>
      <address>
        <city>Pleven</city>
        <zip>4500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT Nadezhda, Medical Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1373</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Tsarisa Yoanna - ISUL</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Georgi Stranski Medical Oncology Department</name>
      <address>
        <city>Sofia</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>COC Dobrich</name>
      <address>
        <city>Sofia</city>
        <zip>9300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>01106</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology, University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>04032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology, Bekec County Hosp</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology, University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology, Tolna County Hospital</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ewa Pilecka Department of Clinical Oncology</name>
      <address>
        <city>Bialystok</city>
        <zip>15027</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>GdaÅ„sk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>I Clinics of Radiotherapy and Chemiotherapy; The Maria Sklodowska-Curie National Research Institute of Oncology</name>
      <address>
        <city>Gliwice</city>
        <zip>44-102</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biokinetica</name>
      <address>
        <city>Jozefow</city>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinics of Head and Neck Cancer, The Maria Sklodowska-Curie National Research Institute of Oncology</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Badajoz</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'HebrÃ³n</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise &quot;City Clinical Hospital#4&quot; of Dnipro City</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-Profit Enterprise &quot;Regional Center of Oncology&quot;, Oncosurgical Department of Head and Neck</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise &quot;Regional Clinical Oncology Center of Kirovohrad Regional Council&quot;,</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncological Centre</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise of Sumy Regional Council &quot;Sumy Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Podilsky Regional Center of Oncology</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

